Rice Hall James & Associates LLC Acquires 32,869 Shares of Viridian Therapeutics, Inc. $VRDN

Posted by Geri Gentry on Jun 16th, 2026

Rice Hall James & Associates LLC grew its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 3.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 884,532 shares of the company’s stock after acquiring an additional 32,869 shares during the quarter. Viridian Therapeutics accounts for about 1.5% of Rice Hall James & Associates LLC’s holdings, making the stock its 16th largest position. Rice Hall James & Associates LLC owned 0.93% of Viridian Therapeutics worth $27,527,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Viridian Therapeutics by 29.6% in the 4th quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock worth $174,650,000 after acquiring an additional 1,280,161 shares during the period. Commodore Capital LP lifted its position in shares of Viridian Therapeutics by 35.4% in the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock worth $68,152,000 after acquiring an additional 1,275,000 shares during the period. State Street Corp lifted its position in shares of Viridian Therapeutics by 35.7% in the 4th quarter. State Street Corp now owns 3,466,560 shares of the company’s stock worth $107,879,000 after acquiring an additional 912,394 shares during the period. Geode Capital Management LLC lifted its position in shares of Viridian Therapeutics by 12.8% in the 4th quarter. Geode Capital Management LLC now owns 1,992,174 shares of the company’s stock worth $62,007,000 after acquiring an additional 225,987 shares during the period. Finally, Fisher Asset Management LLC lifted its position in shares of Viridian Therapeutics by 48.2% in the 4th quarter. Fisher Asset Management LLC now owns 1,780,284 shares of the company’s stock worth $55,402,000 after acquiring an additional 579,058 shares during the period.

Insider Activity

In related news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $17.00 per share, with a total value of $19,999,990.00. Following the acquisition, the director owned 5,090,928 shares in the company, valued at approximately $86,545,776. This represents a 30.05% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on VRDN. Evercore set a $26.00 price objective on Viridian Therapeutics in a research report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Monday, April 20th. Stifel Nicolaus set a $39.00 price objective on Viridian Therapeutics in a research report on Wednesday, May 13th. Wedbush reduced their price objective on Viridian Therapeutics from $37.00 to $31.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. Finally, Truist Financial dropped their target price on Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $36.14.

Check Out Our Latest Stock Analysis on VRDN

Viridian Therapeutics Trading Down 0.3%

Shares of VRDN opened at $16.30 on Tuesday. Viridian Therapeutics, Inc. has a 1 year low of $13.18 and a 1 year high of $34.29. The company has a current ratio of 15.15, a quick ratio of 15.15 and a debt-to-equity ratio of 0.10. The stock has a 50 day simple moving average of $15.91 and a 200-day simple moving average of $25.14. The stock has a market cap of $1.68 billion, a PE ratio of -4.91 and a beta of 0.90.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The business had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.04 million. During the same period in the prior year, the firm posted ($0.87) EPS. Viridian Therapeutics’s quarterly revenue was up 95.8% compared to the same quarter last year. On average, sell-side analysts predict that Viridian Therapeutics, Inc. will post -3.87 EPS for the current fiscal year.

About Viridian Therapeutics

(Free Report)

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.